Leukemia

Sustained improvements in leukemia outcomes in low- and middle-income countries are feasible with cross border programs, according to an expert from the University of California, San Diego.

Voruciclib plus venetoclax appears to yield no dose-limiting toxicities in a small population of patients with acute myeloid leukemia, according to early findings from a phase 1 study.

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia.

Asciminib does not appear to interfere with the general life activities of patients with resistant/intolerant chronic phase chronic myeloid leukemia in the phase 3 ASCEMBL trial.

China’s National Medical Products Administration has also approved zanubrutinib as a treatment for patients with Waldenström macroglobulinemia based on findings from the phase 3 ASPEN trial.

The novel radiotherapy Iomab-B prolongs survival and improves clinical outcomes among patients with relapsed/refractory acute myeloid leukemia, according to data from the phase 3 SIERRA trial.

The FDA extends the Prescription Drug User Fee Act date to July 24, 2023 for quizartinib in the management of newly diagnosed FLT3-ITD mutation–positive acute myeloid leukemia.

Despite an improvement in disease-free survival, patients 60 years or over with acute myeloid leukemia do not appear to have a survival benefit from allo-HCT during first complete remission compared with consolidation chemotherapy.

Jun J. Yang, PhD, reviews the use of ex vivo drug sensitivity profiles and in vivo early treatment response for patients with acute lymphoblastic leukemia.

Investigators highlight the importance of building partnerships between CAR T-cell centers and external hospitals to increase treatment referrals and access to clinical trials for patients with B-cell acute lymphoblastic leukemia.

A patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.

Experts on graft-vs-host disease offer clinical insights for clinicians treating patients with GVHD.

Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical practice.

A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

An esteemed panel of experts overviews new approaches being explored for treating graft-vs-host disease.

A detailed discussion on first-line treatment options for chronic GVHD and options for patients with steroid-refractory chronic GVHD.

Experts on graft-vs-host disease discuss patient monitoring and education, and a patient details his experience with GVHD.

A panel of GVHD experts give a comprehensive overview of the presentations of acute and chronic graft-vs-host disease.

Experts on graft-vs-host disease review GVHD and methods of prophylaxis preceding transplant.

A panel of experts and a patient with graft-vs-host disease discuss the relationship between transplantation and GVHD.

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

Further research is necessary to determine whether regular DNA sequence testing for residual disease variants in patients with acute myeloid leukemia can improve outcomes.

An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.

At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .

An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.

Adult patients with chronic lymphocytic leukemia in the European Union can now receive treatment with acalabrutinib tablets.

The panel shares some final thoughts on unmet needs and the future of CLL treatment.

Dr Alexey Danilov explains data on emerging therapies, including anti-ROR1 therapies, BTK degrading agents, and bispecifics, for treatment of CLL.

The panel shares their thoughts on sequencing the available therapies in patients with CLL.

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.